FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei

  • Julien DubreuilEmail author
  • Francesco Giammarile
  • Pascal Rousset
  • Naoual Bakrin
  • Guillaume Passot
  • Sylvie Isaac
  • Olivier Glehen
  • Andrea Skanjeti
Original Article



Pseudomyxoma peritonei (PMP) is a rare peritoneal neoplasm originating from appendicular tumours. There is no consolidated data available in the literature about the precise role of [18F] fluorodesoxy-D-glucose Positron Emission Tomography / contrast enhanced Computed Tomography (FDG-PET/ceCT). The aim of this study was to evaluate the correlation between preoperative FDG-PET/ceCT (qualitative and semi-quantitative assessment) and progression free survival (PFS) of patients treated for PMP.


All patients scheduled for PMP treatment by cytoreductive unicentric surgery, intraperitoneal chemotherapy (HIPEC), and who underwent a FDG-PET/ceCT between February 2008 and January 2014, were included. No previous treatment was performed (except biopsy or appendectomy). FDG-PET/ceCT was interpreted by two nuclear physicians in consensus. Positive FDG-PET/ceCT scans were further labelled in diffuse disease and poly/mono focal disease. SUVmax was measured based on post-operative reports. The Peritoneal Cancer Index (PCI) and Completeness of CytoReduction Score (CCR) were assessed after surgery.


Fifty-six patients were included in this study, with a mean age of 56-years-old and a mean follow-up of 29.3 months. SUVmax, with a cut-off at 2.02, was predictive for the PFS on multivariate analysis. No differences were observed between diffuse disease and focal disease on PFS for progression free survival, PCI, and SUVmax (p = 0.1). Post-operative CCR was not significantly correlated with SUVmax or FDG-PET/ceCT qualitative assessment.


SUVmax on preoperative FDG-PET/ceCT was an independent predictive factor for PFS in PMP. Further studies are needed to explore if FDG-PET/ceCT could potentially predict post-operative CCR.


Pseudomyxoma peritonei FDG-PET/ceCT Recurrence Prognosis Intraperitoneal chemotherapy 



The authors gratefully acknowledge the assistance of Isabelle Bonnefoy on data collection and of Eda Koxhaku on English editing.

Compliance with ethical standards

Conflicts of interest




Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196–201.CrossRefPubMedGoogle Scholar
  2. 2.
    van den Heuvel MG, Lemmens VE, Verhoeven RH, de Hingh IH. The incidence of mucinous appendiceal malignancies: a population-based study. Int J Color Dis. 2013;28:1307–10.CrossRefGoogle Scholar
  3. 3.
    Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233–80.PubMedGoogle Scholar
  4. 4.
    Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54:293–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Dirisamer A, Schima W, Heinisch M, Weber M, Lehner HP, Haller J, et al. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol. 2009;69:536–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Passot G, Glehen O, Pellet O, Isaac S, Tychyj C, Mohamed F, et al. Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction. Eur J Surg Oncol. 2010;36:315–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Gilly FN, Cotte E, Brigand C, Monneuse O, Beaujard AC, Freyer G, et al. Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol. 2006;32:597–601.CrossRefPubMedGoogle Scholar
  10. 10.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19:1390–408.CrossRefPubMedGoogle Scholar
  13. 13.
    Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000;174:1005–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Misdraji J. Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei. Mod Pathol. 2015;28 Suppl 1:S67–79.CrossRefPubMedGoogle Scholar
  15. 15.
    Villeneuve L, Isaac S, Glehen O, Capovilla M, Chevallier A, Croce S, et al. The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists. Ann Pathol. 2014;34:4–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Basu S, Alavi A. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging. 2007;34:1527–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Teo BK, Seo Y, Bacharach SL, Carrasquillo JA, Libutti SK, Shukla H, et al. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med. 2007;48:802–10.PubMedGoogle Scholar
  18. 18.
    Hatt M, Le Pogam A, Visvikis D, Pradier O, Cheze Le Rest C. Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer. J Nucl Med. 2012;53:12–20.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Basu S, Baghel NS. Value of delayed PET imaging in mucinous adenocarcinoma rectum: should this be employed while evaluating mucinous tumors with FDG-PET? Indian J Cancer. 2011;48:374–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Chua TC, Al-Zahrani A, Saxena A, Glenn D, Liauw W, Zhao J, et al. Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2011;18:1582–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Julien Dubreuil
    • 1
    • 2
    Email author
  • Francesco Giammarile
    • 3
    • 4
  • Pascal Rousset
    • 2
    • 5
  • Naoual Bakrin
    • 6
  • Guillaume Passot
    • 7
  • Sylvie Isaac
    • 8
  • Olivier Glehen
    • 2
    • 7
    • 9
  • Andrea Skanjeti
    • 1
    • 2
  1. 1.Nuclear Medicine and PET UnitCentre Hospitalier Lyon-Sud, Hospices Civils de LyonPierre-BéniteFrance
  2. 2.Equipe Mixte de Recherche 3738Université Claude Bernard Lyon 1LyonFrance
  3. 3.Nuclear Medicine DepartmentGroupement Hospitalier EstBronFrance
  4. 4.Biophysique - Faculté Charles Mérieux LyonLyonFrance
  5. 5.Radiology DepartmentCentre Hospitalier Lyon-Sud, Hospices Civils de LyonPierre-BéniteFrance
  6. 6.Gynaecology DepartmentGroupement Hospitalier Est, Hospices Civils de LyonBronFrance
  7. 7.General and oncologic surgery DepartmentCentre Hospitalier Lyon-Sud, Hospices Civils de LyonPierre-BéniteFrance
  8. 8.Pathology DepartmentCentre Hospitalier Lyon-Sud, Hospices Civils de LyonPierre-BéniteFrance
  9. 9.Lyon 1 UniversityVilleurbanneFrance

Personalised recommendations